Page 118 - 80 guidelines for the treatment of malaria_opt

nd
Guidelines for the treatment of malaria – 2 edition

18. Slutsker LM et al. Mefloquine therapy for Plasmodium falciparum malaria in children under
5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration
with parasitological outcome. Bulletin of the World Health Organization, 1990, 68:53–59.
19. Karbwang J et al. Pharmacokinetics and pharmacodynamics of mefloquine in Thai
patients with acute falciparum malaria. Bulletin of the World Health Organization, 1991,
69:207–212.
20. Nosten F et al. Mefloquine pharmacokinetics and resistance in children with acute
falciparum malaria. British Journal of Clinical Pharmacology, 1991, 31:556–559.
21. Svensson US et al. Population pharmacokinetic and pharmacodynamic modelling of
artemisinin and mefloquine enantiomers in patients with falciparum malaria. European
Journal of Clinical Pharmacology, 2002, 58:339–351.
22. Gimenez F et al. Stereoselective pharmacokinetics of mefloquine in healthy Caucasians
after multiple doses. Journal of Pharmaceutical Sciences, 1994, 83:824–827.
23. Bourahla A et al. Stereoselective pharmacokinetics of mefloquine in young children.
European Journal of Clinical Pharmacology, 1996, 50:241–244.
24. Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports
of severe psychiatric reactions and convulsions. Journal of Tropical Medicine and Hygiene,
1992, 95:167–179.
25. ter Kuile FO et al. Mefloquine treatment of acute falciparum malaria: a prospective study
of non-serious adverse effects in 3673 patients. Bulletin of the World Health Organization,
1995, 73:631–642.
26. Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents.
Fact or fiction? Drug Safety, 1995, 12:370–383.
27. Mai NTH et al. Post-malaria neurological syndrome. Lancet, 1996, 348:917–921.
28. Supanaranond W et al. Lack of a significant adverse cardiovascular effect of combined
quinine and mefloquine therapy for uncomplicated malaria. Transactions of the Royal
Society of Tropical Medicine and Hygiene, 1997, 91:694–696.
29. Eckstein-Ludwig U et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature,
2003, 424:957–961.
30. Navaratnam V et al. Pharmacokinetics of artemisinin-type compounds. Clinical
Pharmacokinetics, 2000, 39:255–270.
31. Ashton M, Nguyen DS, Nguyen VH, et al. Artemisinin kinetics and dynamics during oral
and rectal treatment of uncomplicated malaria. Clinical Pharmacology and Therapeutics,
1998, 63:482–493.
32. Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives. A review of published and
unpublished clinical trials. Médicine Tropical (Mars), 1998, 58(3 Suppl.):50–53.
33. Price R et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin
derivatives. American Journal of Tropical Medicine and Hygiene, 1999, 60:547–555.
34. Leonardi E et al. Severe allergic reactions to oral artesunate: a report of two cases.
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95:182–183.
35. Van Vugt M et al. A case-control auditory evaluation of patients treated with artemisinin
derivatives for multidrug-resistant Plasmodium falciparum malaria. American Journal of
Tropical Medicine and Hygiene, 2000, 62:65–69.
104